Nonhlanhla N Mkhize
Overview
Explore the profile of Nonhlanhla N Mkhize including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
788
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cohen P, Lambson B, Mkhize N, Moodley C, Yssel A, Moyo-Gwete T, et al.
J Virol
. 2025 Jan;
99(2):e0173024.
PMID: 39817771
The Antibody Mediated Prevention (AMP) trials showed that passively infused VRC01, a broadly neutralizing antibody (bNAb) targeting the CD4 binding site (CD4bs) on the HIV-1 envelope protein (Env), protected against...
2.
Violari A, Otwombe K, Hahn W, Chen S, Josipovic D, Baba V, et al.
medRxiv
. 2024 Nov;
PMID: 39484284
Background: The neonatal immune system is uniquely poised to generate broadly neutralizing antibodies (bnAbs) and thus infants are ideal for evaluating HIV vaccine candidates. We present the design and safety...
3.
Naicker V, Laher F, Bekker L, Seaton K, Allen M, De Rosa S, et al.
PLOS Glob Public Health
. 2024 Sep;
4(9):e0003319.
PMID: 39302924
Induction of broad, durable immune responses is a challenge in HIV vaccine development. HVTN 100 Part A administered subtype C-containing ALVAC-HIV at months 0 and 1, and ALVAC-HIV with bivalent...
4.
Goga A, Ramraj T, Naidoo L, Daniels B, Matlou M, Chetty T, et al.
BMC Infect Dis
. 2024 Jul;
24(1):712.
PMID: 39033300
Background: The ambitious goal to eliminate new pediatric HIV infections by 2030 requires accelerated prevention strategies in high-risk settings such as South Africa. One approach could be pre-exposure prophylaxis (PrEP)...
5.
Reeves D, Mayer B, deCamp A, Huang Y, Zhang B, Carpp L, et al.
Nat Commun
. 2024 Mar;
15(1):2575.
PMID: 38519455
No abstract available.
6.
Reeves D, Mayer B, deCamp A, Huang Y, Zhang B, Carpp L, et al.
Nat Commun
. 2023 Dec;
14(1):8299.
PMID: 38097552
The Antibody Mediated Prevention (AMP) trials (NCT02716675 and NCT02568215) demonstrated that passive administration of the broadly neutralizing monoclonal antibody VRC01 could prevent some HIV-1 acquisition events. Here, we use mathematical...
7.
Krause R, Moyo-Gwete T, Richardson S, Makhado Z, Manamela N, Hermanus T, et al.
NPJ Vaccines
. 2023 Aug;
8(1):119.
PMID: 37573434
Neutralizing antibodies strongly correlate with protection for COVID-19 vaccines, but the corresponding memory B cells that form to protect against future infection are relatively understudied. Here we examine the effect...
8.
Mkhize N, Yssel A, Kaldine H, van Dorsten R, Woodward Davis A, Beaume N, et al.
PLoS Pathog
. 2023 Jun;
19(6):e1011469.
PMID: 37384759
The VRC01 Antibody Mediated Prevention (AMP) efficacy trials conducted between 2016 and 2020 showed for the first time that passively administered broadly neutralizing antibodies (bnAbs) could prevent HIV-1 acquisition against...
9.
Mahomed S, Garrett N, Capparelli E, Osman F, Mkhize N, Harkoo I, et al.
Lancet HIV
. 2023 Mar;
10(4):e230-e243.
PMID: 37001964
Background: Young women in sub-Saharan Africa continue to bear a high burden of HIV infection. Combination anti-HIV monoclonal antibodies are a potential HIV prevention technology that could overcome adherence challenges...
10.
B Gilbert P, Huang Y, deCamp A, Karuna S, Zhang Y, Magaret C, et al.
Nat Med
. 2022 Aug;
28(9):1924-1932.
PMID: 35995954
The Antibody Mediated Prevention trials showed that the broadly neutralizing antibody (bnAb) VRC01 prevented acquisition of human immunodeficiency virus-1 (HIV-1) sensitive to VRC01. Using AMP trial data, here we show...